UBS sets USD 650.00 target for Chemed stock, 26.11 percent above price

Published on 10/15/2026 at 22:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Chemed schedules third-quarter results for October 27, 2026. Chemed stock costs EUR 459.00 on October 15, 2026 at 10:46 p.m. CEST after hours.

Analyst target and reporting date

UBS Group set a USD 650.00 target and Buy rating on September 25, 2026.
Chemed will release third-quarter 2026 results on October 27, 2026.
Chemed stock costs EUR 459.00 at Lang & Schwarz on October 15, 2026 at 10:46 p.m. CEST.
Chemed's valuation was a P/E ratio of 25.88 and a market capitalization of USD 6.7 billion.

CHE, US16359R1032, Illustration mit AI erstellt.

UBS Group initiated coverage of Chemed with a Buy rating and a USD 650.00 price target on September 25, 2026, according to MarketBeat. Against the NYSE price of USD 515.44 on October 15, 2026, that target was 26.11 percent higher. Chemed stock was trading at EUR 459.00 at Lang & Schwarz on October 15, 2026 at 10:46 p.m. CEST.

October 27 results set the next date

Chemed will release its third-quarter 2026 results after the close of NYSE trading on October 27, 2026. The company will hold its earnings call on October 28 at 10:00 a.m. ET, according to Yahoo Finance. The date gives the stock a defined near-term event after the UBS target entered the analyst picture.

Stock sits below its yearly high

The NYSE quote was last at USD 515.44 on October 15, 2026 at 4:00 p.m. ET. Chemed's 52-week range was USD 365.21 to USD 557.00, placing the price 7.46 percent below the high and 41.13 percent above the low. The session volume was 139,109 shares against an average of 158,439 shares.

MarketBeat reported second-quarter revenue of USD 673.25 million and earnings per share of USD 6.06 on July 28, 2026. Revenue rose 8.80 percent year over year, while fiscal 2026 earnings-per-share guidance stood at USD 25.00 to USD 25.75, according to MarketBeat.

Valuation and peer comparison

Chemed had a market capitalization of USD 6.7 billion, a P/E ratio of 25.88 and a zero dividend yield as of October 15, 2026. The comparison places Chemed between two healthcare-related US stocks on the same day.

Comparison with peers

Chemed: P/E 25.88, market capitalization USD 6.7 billion
Rollins (NYSE, USD): plus 3.86 percent, P/E 30.81, market capitalization USD 16.3 billion
Encompass Health (NYSE, USD): plus 0.96 percent, P/E 20.81, market capitalization USD 12.6 billion

Price remains the immediate market frame

The price position leaves a measurable gap to both the analyst target and the 52-week high. The upcoming October 27 release is the next scheduled company date, while the UBS target supplies the clearest dated valuation reference in the current picture.

Chemed was trading at EUR 459.00 at Lang & Schwarz on October 15, 2026 at 10:46 p.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Chemed stock.